Lionhunter Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Lionhunter Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47M	Buy	+63,045	New	+$1.94M	1.11%	28

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lionhunter Capital Management's RIGL Position: Q2 2026 in Review

Lionhunter Capital Management opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 63,045 shares worth $2.47M. The stake represents 1.11% of the portfolio and ranks #28 among its holdings.

146 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Lionhunter Capital Management held 63,045 shares of Rigel Pharmaceuticals worth $2.47M as of Q2 2026.
Rigel Pharmaceuticals was a new Lionhunter Capital Management position in Q2 2026.
Rigel Pharmaceuticals made up 1.11% of Lionhunter Capital Management's portfolio in Q2 2026, its #28 holding.
146 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Lionhunter Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.